---
title: Ascendia CEO Address Pediatric Formulation Development
description: Ascendia Pharma, founder, and CEO explains the biopharmaceutical considerations and clinical development strategy around pediatric formulations. Read more here.
---

[Pharmaceutical Industry Blog - Ascendia Pharmaceutical Solutions Blog ](https://ascendiacdmo.com/newsroom)

# [Ascendia CEO Address Pediatric Formulation Development](https://ascendiacdmo.com/newsroom/2020/12/30/ascendia-ceo-addresses-age-appropriate-pediatric-formulation-development)

 Written by [Patrick Brightman](https://ascendiacdmo.com/newsroom/author/patrick-brightman) | Dec 30, 2020 5:00:00 AM

In the most recent [Formulation Forum](https://drug-dev.com/formulation-forum-age-appropriate-pediatric-formulation-development/) column, Ascendia Pharmaceutical Solutions founder and CEO Jim Huang, PhD explains the biopharmaceutical considerations and clinical development strategy around pediatric formulations. This is particularly important, considering developing pharmaceuticals for children is extremely challenging due to specific requirements of the patient population.

As the article in *Drug Development & Delivery* explains, a pediatric formulation should consider multiple factors. Among the considerations are:

1. Difference in physiological and pharmacokinetic of patient populations
2. Dosage form selection
3. Route of administration
4. Dose accuracy and flexibility
5. Drug and excipient tolerability (safety and toxicity)
6. Patient compliance (palatability/ swallowability)
7. Stability
8. Drug accessibility

 

You can read Jim’s entire contributed piece, by visiting the [*Drug Development & Delivery* website](https://drug-dev.com/formulation-forum-age-appropriate-pediatric-formulation-development/).

 

[View full post](https://ascendiacdmo.com/newsroom/2020/12/30/ascendia-ceo-addresses-age-appropriate-pediatric-formulation-development)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Patrick Brightman"
  },
  "dateModified" : "2024-12-10T17:10:15.515Z",
  "datePublished" : "2020-12-30T05:00:00Z",
  "headline" : "Ascendia CEO Addresses Age-appropriate Pediatric Formulation Development",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1000,
    "url" : "https://19566523.fs1.hubspotusercontent-na1.net/hubfs/19566523/Imported_Blog_Media/ascendia-pediatric-2.jpg",
    "width" : 1500
  },
  "mainEntityOfPage" : "https://ascendiacdmo.com/newsroom/2020/12/30/ascendia-ceo-addresses-age-appropriate-pediatric-formulation-development",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Newsroom"
  }
}
```